Posted by Michael Wonder on 23 Jan 2023
The EMA validated regulatory application for arpraziquantel, a potential treatment for schistosomiasis in pre-school aged children
23 January 2023 - Arpraziquantel is the first investigational drug in regulatory phase amongst the different projects supported by the Global Health Innovative Technology Fund.
Since 2013, the Global Health Innovative Technology Fund supported and invested in the Paediatric Praziquantel Consortium, a public private partnership dedicated to the development of arpraziquantel, a potential new treatment option for schistosomiasis in pre-school aged children (3 months to 6 years of age).
